טוען...
Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis
BACKGROUND: Ipilimumab is a fully human monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 , a key negative regulator of T-cell activation approved by the Food and Drug Administration as of March 2011 for the treatment of metastatic melanoma. As a result of the up-regulation of th...
שמור ב:
| הוצא לאור ב: | BMC Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4350587/ https://ncbi.nlm.nih.gov/pubmed/25885696 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1074-7 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|